Imagine a life-changing drug for a devastating rare disease, pulled from public view just as families were clinging to hope. That's exactly what happened when the National Centre for Pharmacoeconomics (NCPE) removed its assessment of a Duchenne Muscular Dystrophy (DMD) drug from its website at the request of the Department of Health. But here's where it gets controversial: the NCPE's recommendation was clear – the drug, Givinostat (brand name Duvyzat), shouldn't be publicly funded unless its cost-effectiveness improves. This decision, while financially prudent, leaves families of children with DMD in a heartbreaking limbo.
DMD, a condition primarily affecting young boys, causes progressive muscle weakness, leading to scoliosis, wheelchair dependence, and life-threatening complications like pneumonia. Current treatments, including steroids and various therapies, cost between €10,000 and €15,000 annually. Duvyzat, however, comes with a staggering price tag of €92,000 to €334,000 per patient per year, depending on weight. The NCPE's assessment, briefly available online, revealed a potential five-year budget impact for the HSE exceeding €26 million, possibly reaching €58 million if all eligible patients (estimated at around 50) were treated.
And this is the part most people miss: while the NCPE’s detailed technical summary and plain English version for the public were removed, the core finding remains – the drug’s current cost-effectiveness doesn’t justify public funding. NCPE Clinical Director Professor Michael Barry confirmed the removal, stating it was done with the understanding that the findings could be published soon.
This development coincides with Health Minister Jennifer Carroll MacNeill’s address to the Irish Pharmaceutical Healthcare Association (IPHA) conference, where a new four-year drugs deal between the IPHA and the Government was recently announced. The NCPE, comprising clinicians, pharmacists, pharmacologists, and statisticians, plays a crucial role in evaluating the benefits and costs of medical technologies, advising the HSE on public funding decisions.
Duvyzat, classified as an orphan medicine for rare diseases, is intended for patients aged six and older, used alongside steroid treatment. The NCPE’s full assessment, reviewed by RTÉ News, reiterates that the drug should not be reimbursed unless its cost-effectiveness improves.
For families of children with DMD, this is more than a financial debate – it’s about hope and quality of life. Children with DMD face delayed motor development, wheelchair dependence by ages 10-12, and severe complications like restrictive lung disease. Duvyzat offers a glimmer of possibility, but at what cost?
Is it fair to deny access to a potentially life-changing drug due to its high cost, or should public funding prioritize affordability over innovation? This question sparks a heated debate, and we want to hear your thoughts. Share your perspective in the comments – let’s discuss the balance between financial responsibility and the value of life-changing treatments.
